Merck to Announce Multiple Scientific Efforts to Combat COVID-19
KENILWORTH, N.J.--(BUSINESS WIRE) May 26, 2020 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, will today announce three significant scientific initiatives to combat COVID-19: two agreements to develop potential vaccines... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 26, 2020 Category: Pharmaceuticals Source Type: clinical trials

Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
KENILWORTH, N.J.& MIAMI--(BUSINESS WIRE) May 26, 2020 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics LP, a closely held biotechnology company, today announced that the companies have... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 26, 2020 Category: Pharmaceuticals Source Type: clinical trials

IAVI and Merck Collaborate to Develop Vaccine Against SARS-CoV-2
KENILWORTH, N.J.& NEW YORK--(BUSINESS WIRE) May 26, 2020 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, and IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 26, 2020 Category: Pharmaceuticals Source Type: clinical trials

Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine
GAITHERSBURG, Md., May 25, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced enrollment of the first... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 25, 2020 Category: Pharmaceuticals Source Type: clinical trials

AstraZeneca Advances Response to Global COVID-19 Challenge as it Receives First Commitments for Oxford ’s Potential New Vaccine
21 May 2020 -- AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford’s vaccine widely... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 21, 2020 Category: Pharmaceuticals Source Type: clinical trials

Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)
WALTHAM, Mass., May 21, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced plans to submit a New Drug Application (NDA) for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 21, 2020 Category: Pharmaceuticals Source Type: clinical trials

Kadmon Announces Positive Topline Results of Pivotal Trial of Belumosudil (KD025) in Chronic Graft-Versus-Host Disease
NEW YORK, NY / ACCESSWIRE / May 21, 2020 / Kadmon Holdings, Inc. (NYSE:KDMN) today announced positive topline results from the primary analysis of ROCKstar (KD025-213), the pivotal trial evaluating belumosudil (KD025) in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 21, 2020 Category: Pharmaceuticals Source Type: clinical trials

New Longer-Term Data Reinforce Safety of Genentech ’s Satralizumab in Adults and Adolescents With Neuromyelitis Optica Spectrum Disorder (NMOSD)
South San Francisco, CA -- May 21, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new pooled pivotal satralizumab safety results for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 21, 2020 Category: Pharmaceuticals Source Type: clinical trials

Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcerative Colitis
FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--May 20, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext& Nasdaq: GLPG) today announced positive topline results from SELECTION, a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 20, 2020 Category: Pharmaceuticals Source Type: clinical trials

Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 18, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 18, 2020 Category: Pharmaceuticals Source Type: clinical trials

Janssen Presents First Data from Phase 1 Study of BCMAxCD3 Bispecific Teclistamab in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
BEERSE, Belgium--(BUSINESS WIRE) May 18, 2020 --The Janssen Pharmaceutical Companies of Johnson& Johnson announced today results reported for the first time from a Phase 1 first-in-human dose escalation study (NCT03145181) of teclistamab... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 18, 2020 Category: Pharmaceuticals Source Type: clinical trials

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations
RARITAN, N.J., May 18, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson& Johnson announced today results from the Phase 1 CHRYSALIS study (NCT02609776) evaluating amivantamab (JNJ-6372) in the treatment... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 18, 2020 Category: Pharmaceuticals Source Type: clinical trials

Investigational ChAdOx1 nCoV-19 Vaccine Protects Monkeys Against COVID-19 Pneumonia
Friday, May 15, 2020 -- A single dose of ChAdOx1 nCoV-19, an investigational vaccine against SARS-CoV-2, has protected six rhesus macaques from pneumonia caused by the virus, according to National Institutes of Health scientists and University of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 16, 2020 Category: Pharmaceuticals Source Type: clinical trials

Pfizer ’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study
NEW YORK--(BUSINESS WIRE) - May 15, 2020 -- Pfizer Inc. (NYSE: PFE) today announced updated Phase 1b clinical data on PF-06939926, an investigational gene therapy being developed to treat Duchenne muscular dystrophy (DMD). The preliminary data from... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 15, 2020 Category: Pharmaceuticals Source Type: clinical trials

STI-1499, A Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies
SAN DIEGO, May 15, 2020 /PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, " Sorrento " ) announced today that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 15, 2020 Category: Pharmaceuticals Source Type: clinical trials

Pfizer Announces Positive Top-Line Results From Phase 3 Lot Consistency Study of 20-Valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naive Adults 18 Through 49 Years of Age
NEW YORK--(BUSINESS WIRE) May 14, 2020 -- Pfizer Inc. (NYSE:PFE) today announced top-line results from a second Phase 3 study (NCT03828617), which described the safety and evaluated the consistency of immune responses elicited across three different... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 14, 2020 Category: Pharmaceuticals Source Type: clinical trials

Neuraptive Therapeutics Announces FDA has Granted Fast Track Designation to NTX-001 Clinical Development Program for Treatment of Patients with Peripheral Nerve Injuries
PHILADELPHIA--(BUSINESS WIRE)--May 14, 2020 -- Neuraptive Therapeutics, Inc. (Neuraptive), a clinical-stage biotechnology company dedicated to developing novel therapeutics and medical products for treatment of peripheral nerve injuries (PNI), today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 14, 2020 Category: Pharmaceuticals Source Type: clinical trials

Sunovion Discontinues Dasotraline Program
May 13, 2020 -- MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has withdrawn the New Drug Applications (NDAs) for dasotraline, a novel dopamine and norepinephrine reuptake inhibitor... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 14, 2020 Category: Pharmaceuticals Source Type: clinical trials

Merck ’s Novel HIF-2α Inhibitor Showed an Objective Response Rate of Nearly 30% in Patients with von Hippel-Lindau (VHL) Disease-Associated Clear Cell Renal Cell Carcinoma
KENILWORTH, N.J.--(BUSINESS WIRE) May 13, 2020 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time results from a Phase 2 trial evaluating the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 13, 2020 Category: Pharmaceuticals Source Type: clinical trials

Genentech to Present First Clinical Data on Novel Anti-TIGIT Cancer Immunotherapy Tiragolumab at ASCO
South San Francisco, CA -- May 13, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase II CITYSCAPE trial, the first randomized study evaluating the efficacy and safety of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 13, 2020 Category: Pharmaceuticals Source Type: clinical trials

Janssen ’s BCMA CAR-T Therapy JNJ-4528 Showed Early, Deep and Durable Responses in Heavily Pretreated Patients with Multiple Myeloma
RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson& Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-4528, an... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 13, 2020 Category: Pharmaceuticals Source Type: clinical trials

Bristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma
PRINCETON, N.J.,& CAMBRIDGE, Mass.--(BUSINESS WIRE) May 13, 2020 --Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the companies received a Refusal to File letter from the U.S. Food and Drug... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 13, 2020 Category: Pharmaceuticals Source Type: clinical trials

Moderna Receives FDA Fast Track Designation for mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 12, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 13, 2020 Category: Pharmaceuticals Source Type: clinical trials

Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One of the National Institutes of Health
NEWTON, MA – May 11, 2020– Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 11, 2020 Category: Pharmaceuticals Source Type: clinical trials

RedHill Biopharma Receives FDA Approval for COVID-19 Clinical Study with Opaganib in the U.S.
TEL-AVIV, Israel and RALEIGH, NC, May 8, 2020, RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the“Company”), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 9, 2020 Category: Pharmaceuticals Source Type: clinical trials

FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., May 8, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 8, 2020 Category: Pharmaceuticals Source Type: clinical trials

U.S. FDA Clears Pluristem ’s IND Application for Phase II COVID-19 Study
HAIFA, Israel, May 08, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 8, 2020 Category: Pharmaceuticals Source Type: clinical trials

Gilead Announces Approval of Veklury ® (remdesivir) in Japan for Patients With Severe COVID-19
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 7, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 8, 2020 Category: Pharmaceuticals Source Type: clinical trials

Evelo Biosciences, Rutgers University, and Robert Wood Johnson University Hospital Announce Submission of IND for a Phase 2 Study of EDP1815 in COVID-19 Patients
CAMBRIDGE, Mass. and NEW BRUNSWICK, N.J., May 07, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), Rutgers University, and Robert Wood Johnson University Hospital today announced the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 7, 2020 Category: Pharmaceuticals Source Type: clinical trials

Tonix Pharmaceuticals Enters into Research Collaboration and Exclusive License Agreement with University of Alberta to Develop Novel Horsepox-Based Vaccines, TNX-1810, TNX-1820 and TNX-1830, for the Prevention of COVID-19
NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, and the University of Alberta, a leading Canadian research university, announced today... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 7, 2020 Category: Pharmaceuticals Source Type: clinical trials

First Patient Dosed in FDA-Approved Phase III Lenzilumab Study for COVID-19
Burlingame, CA, May 6, 2020 – Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 7, 2020 Category: Pharmaceuticals Source Type: clinical trials

Sinovac Announces First Animal Study Results of Vaccine Against COVID-19 Published in SCIENCE
BEIJING -- Sinovac Biotech Ltd. May 06, 2020 -- (NASDAQ: SVA) (“Sinovac” or the“Company”), a leading provider of biopharmaceutical products in China, announced today the publication of the preclinical study on animals for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 7, 2020 Category: Pharmaceuticals Source Type: clinical trials

Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program
NEW YORK& MAINZ, Germany--(BUSINESS WIRE) May 5, 2020 --Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 6, 2020 Category: Pharmaceuticals Source Type: clinical trials

Akebia Therapeutics Announces Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
CAMBRIDGE, Mass., May 5, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced positive top-line... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 5, 2020 Category: Pharmaceuticals Source Type: clinical trials

DelMar Pharmaceuticals Provides Enrollment Update in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors
SAN DIEGO, May 5, 2020 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ( " DelMar " or the " Company " ), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today it has enrolled 22... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 5, 2020 Category: Pharmaceuticals Source Type: clinical trials

Lilly and Junshi Biosciences to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19
SHANGHAI and INDIANAPOLIS, May 4, 2020 /PRNewswire/ -- Junshi Biosciences (HKEX: 1877) and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop therapeutic antibodies for the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 4, 2020 Category: Pharmaceuticals Source Type: clinical trials

Gilead ’s Investigational Antiviral Remdesivir Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of COVID-19
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 1, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the investigational... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 2, 2020 Category: Pharmaceuticals Source Type: clinical trials

Moderna and Lonza Announce Worldwide Strategic Collaboration to Manufacture Moderna ’s Vaccine (mRNA-1273) Against Novel Coronavirus
CAMBRIDGE, Mass. & BASEL, Switzerland--(BUSINESS WIRE)--May 1, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 2, 2020 Category: Pharmaceuticals Source Type: clinical trials

Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15
Saint Herblain (France) and New York, NY, April 30, 2020 – Valneva SE (“Valneva”), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize Valneva’s Lyme... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 1, 2020 Category: Pharmaceuticals Source Type: clinical trials

INOVIO Expands Manufacturing of COVID-19 DNA Vaccine INO-4800 With New Funding from CEPI
PLYMOUTH MEETING, Pa., April 30, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced it has entered into an agreement to expand its manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH& Co. KG,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 30, 2020 Category: Pharmaceuticals Source Type: clinical trials

CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries
VANCOUVER, Washington, April 30, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the“Company " ), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 30, 2020 Category: Pharmaceuticals Source Type: clinical trials

AstraZeneca and Oxford University Announce Landmark Agreement for COVID-19 Vaccine
30 April 2020 -- AstraZeneca and the University of Oxford today announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 30, 2020 Category: Pharmaceuticals Source Type: clinical trials

Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19
FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 29, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 30, 2020 Category: Pharmaceuticals Source Type: clinical trials

Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases ’ Study of Investigational Antiviral Remdesivir for COVID-19
FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 29, 2020-- Gilead Sciences. Inc. (Nasdaq: GILD) is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 30, 2020 Category: Pharmaceuticals Source Type: clinical trials

First Patient Dosed in Avdoralimab Phase II Clinical Trial in COVID-19 Patients With Severe Pneumonia
MARSEILLE, France, April 28, 2020 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH– ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the“Company”) today announced that the first patient was dosed in a... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 29, 2020 Category: Pharmaceuticals Source Type: clinical trials

Bergenbio ’s Bemcentinib Selected To Be Fast-Tracked As Potential Treatment For Covid-19 Through New National UK Government Clinical Trial Initiative
Bergen, Norway, 28 April 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, announces that bemcentinib has been selected as the first... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 28, 2020 Category: Pharmaceuticals Source Type: clinical trials

Sanofi and Regeneron Provide Update on U.S. Kevzara Phase 2/3 Adaptive-Designed Trial in Hospitalized COVID-19 Patients
Paris and Tarrytown, N.Y. April 27, 2020– Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzara® (sarilumab), an... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 28, 2020 Category: Pharmaceuticals Source Type: clinical trials

GSK Presents New Data from the GARNET Study Demonstrating Potential of Dostarlimab to Treat a Subset of Women with Recurrent or Advanced Endometrial Cancer
London, UK 23 April 2020 -- GlaxoSmithKline plc today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1) monoclonal antibody, provided clinically... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 28, 2020 Category: Pharmaceuticals Source Type: clinical trials

Moderna Announces IND Submitted to U.S. FDA for Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 27, 2020-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 28, 2020 Category: Pharmaceuticals Source Type: clinical trials

Genentech ’s Risdiplam Shows Significant Improvement in Survival and Motor Milestones in Infants With Type 1 Spinal Muscular Atrophy (SMA)
South San Francisco, CA -- April 27, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today presented 1-year data from FIREFISH Part 2, a pivotal global study evaluating risdiplam in infants aged 1-7 months old with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 27, 2020 Category: Pharmaceuticals Source Type: clinical trials